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background: ApoC-III plays a pivotal role in regulating plasma triglyceride (TG) levels by inhibiting the hydrolysis of TG-rich lipoproteins and the 
receptor-mediated uptake of lipoprotein remnants by the liver and is recognized as a CV risk factor. ISIS-ApoCIIIRx selectively inhibits apoC-III 
protein synthesis in the liver. This study assessed the change from baseline in lipids and lipoprotein particles following treatment with ISIS-ApoCIIIRx 
in patients with hypertriglyceridemia (HTG) on a fibrate.
methods: In this double-blind Phase 2 study, patients ≥18 years with TG levels ≥225 & ≤2000 mg/dL on a fibrate were randomized 2:1 to receive 
ISIS-ApoCIIIRx or placebo as weekly 200 (n=12) or 300 mg (n=16) SC injections for 13 weeks. Baseline and end-of-treatment plasma samples were 
analyzed for lipoproteins (ultracentrifugation; Medpace) and lipoprotein particle number and size (NMR spectroscopy; LipoScience).
results: Pharmacodynamic results showed sustained dose-dependent reductions in atherogenic lipids. The mean percent change in total apoC-III, 
TG, VLDL apoC-III and VLDL-C was -59, -50, -66, -52% (200 mg) and -70, -64, -77, -64% (300 mg), respectively, while HDL-C increased 47% (200 mg) 
and 52% (300 mg). Changes were sustained for at least 6 weeks after the last dose. Non-HDL-C, apoB, LDL-C, and total cholesterol levels remained 
unchanged. Significant dose dependent reductions in total and subclass VLDL particle numbers, and increases in total HDL particle and large LDL 
particle numbers and LDL size (with no change in the total number of LDL particles) were observed. ISIS-ApoCIIIRx was generally safe and well 
tolerated. There were no clinically meaningful changes in liver tests or other laboratory values and no abnormalities in renal function.
conclusions: Reduction in apoC-III in HTG patients on a fibrate enhanced hydrolysis of VLDL which resulted in fewer VLDL particles and an 
increase in LDL particle size, but not number. An increase in the number of HDL particles occurred in parallel with a substantial increase in HDL-C. 
Overall, the results demonstrate an improved atherogenic profile in HTG patients following treatment with ISIS-ApoCIIIRx.
